Safety and pharmacokinetics of XOMA 3AB, A novel mixture of three monoclonal antibodies against botulinum toxin A

导出原文传递

翻译打印收藏纠错

作者： Nayak,S.U. ^[1] ; Griffiss,J.M. ^[2] ; McKenzie,R. ^[3] ; Fuchs,E.J. ^[4] ; Jurao,R.A. ; An,A.T. ; Ahene,A. ; Tomic,M. ; Hendrix,C.W. ; Zenilman,J.M.

作者单位： Clinical RM, Inc., Hinckley, OH, United States ^[1] Johns Hopkins University, Baltimore, MD, United States ^[2] XOMA Corporation, Berkeley, CA, United States ^[3] Johns Hopkins University, Baltimore, MD, United States, Ross University School of Medicine, Roseau ^[4]

发布时间 2014-12-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Antimicrobial Agents and Chemotherapy

2014年58卷9期

5047-5053页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety and pharmacokinetics of XOMA 3AB, A novel mixture of three monoclonal antibodies against botulinum toxin A

Antimicrobial Agents and Chemotherapy

相似文献

Antimicrobial Agents and Chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety and pharmacokinetics of XOMA 3AB, A novel mixture of three monoclonal antibodies against botulinum toxin A

Antimicrobial Agents and Chemotherapy

相似文献

Antimicrobial Agents and Chemotherapy

相关期刊

检索历史清除